RU2771275C2 - Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения - Google Patents

Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения Download PDF

Info

Publication number
RU2771275C2
RU2771275C2 RU2017119222A RU2017119222A RU2771275C2 RU 2771275 C2 RU2771275 C2 RU 2771275C2 RU 2017119222 A RU2017119222 A RU 2017119222A RU 2017119222 A RU2017119222 A RU 2017119222A RU 2771275 C2 RU2771275 C2 RU 2771275C2
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
ketamine
acceptable salt
norketamine
compound
Prior art date
Application number
RU2017119222A
Other languages
English (en)
Russian (ru)
Other versions
RU2017119222A3 (cg-RX-API-DMAC7.html
RU2017119222A (ru
Inventor
Алекс НИВОРОЖКИН
Нельсон ЛАНДРАУ
Original Assignee
Аморса Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аморса Терапьютикс, Инк. filed Critical Аморса Терапьютикс, Инк.
Publication of RU2017119222A publication Critical patent/RU2017119222A/ru
Publication of RU2017119222A3 publication Critical patent/RU2017119222A3/ru
Application granted granted Critical
Publication of RU2771275C2 publication Critical patent/RU2771275C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2017119222A 2014-11-04 2015-11-04 Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения RU2771275C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074645P 2014-11-04 2014-11-04
US62/074,645 2014-11-04
PCT/US2015/059113 WO2016073653A1 (en) 2014-11-04 2015-11-04 Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Publications (3)

Publication Number Publication Date
RU2017119222A RU2017119222A (ru) 2018-12-06
RU2017119222A3 RU2017119222A3 (cg-RX-API-DMAC7.html) 2019-06-07
RU2771275C2 true RU2771275C2 (ru) 2022-04-29

Family

ID=55909773

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017119222A RU2771275C2 (ru) 2014-11-04 2015-11-04 Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения

Country Status (18)

Country Link
US (5) US10252982B2 (cg-RX-API-DMAC7.html)
EP (2) EP3215147B1 (cg-RX-API-DMAC7.html)
JP (2) JP6882180B2 (cg-RX-API-DMAC7.html)
KR (1) KR102604397B1 (cg-RX-API-DMAC7.html)
CN (2) CN115521217A (cg-RX-API-DMAC7.html)
AU (1) AU2015343083B2 (cg-RX-API-DMAC7.html)
CA (1) CA2966737A1 (cg-RX-API-DMAC7.html)
DK (1) DK3215147T3 (cg-RX-API-DMAC7.html)
ES (1) ES2977383T3 (cg-RX-API-DMAC7.html)
FI (1) FI3215147T3 (cg-RX-API-DMAC7.html)
HU (1) HUE066468T2 (cg-RX-API-DMAC7.html)
LT (1) LT3215147T (cg-RX-API-DMAC7.html)
PL (1) PL3215147T3 (cg-RX-API-DMAC7.html)
PT (1) PT3215147T (cg-RX-API-DMAC7.html)
RS (1) RS65411B1 (cg-RX-API-DMAC7.html)
RU (1) RU2771275C2 (cg-RX-API-DMAC7.html)
SI (1) SI3215147T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016073653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
PL3272338T3 (pl) 2014-04-17 2021-01-11 Develco Pharma Schweiz Ag Doustna postać dawkowania ketaminy
EP3215147B1 (en) * 2014-11-04 2024-02-28 ACADIA Pharmaceuticals Inc. Neuro-attenuating norketamine compounds and methods
WO2016186968A1 (en) * 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN108884019A (zh) * 2016-04-11 2018-11-23 克雷西奥生物科技有限公司 氘代氯胺酮衍生物
CN110035997A (zh) * 2016-09-16 2019-07-19 生物制药沃克斯有限公司 羟基去甲氯胺酮前药
US20190240184A1 (en) * 2016-10-27 2019-08-08 National University Corporation Chiba University Pharmaceutical applications for (s)-norketamine and salts thereof
MX2019012285A (es) 2017-04-13 2020-11-06 Ovid Therapeutics Inc Metodos de tratamiento de encefalopatias del desarrollo.
EP3641742A2 (en) * 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
PL3532457T3 (pl) 2017-07-31 2020-10-19 Small Pharma Ltd Postacie krystaliczne hydroksynorketaminy
CN111630026A (zh) * 2017-10-10 2020-09-04 道格拉斯制药有限公司 缓释药物制剂和治疗方法
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CN112533595A (zh) 2018-05-04 2021-03-19 感知神经科学公司 治疗物质滥用的方法
CA3103440A1 (en) 2018-06-27 2020-01-02 Clexio Biosciences Ltd. Method of treating major depressive disorder
AU2019352028A1 (en) 2018-10-05 2021-03-11 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
JP7381597B2 (ja) * 2019-03-25 2023-11-15 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20230029301A1 (en) * 2019-08-06 2023-01-26 The Regents Of The University Of California Scaleable preparation of polyketides
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
WO2021137148A1 (en) * 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
US11597726B2 (en) 2020-05-20 2023-03-07 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114524737B (zh) * 2020-11-23 2024-10-22 江苏恒瑞医药股份有限公司 一种取代的环己酮类化合物
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022232693A1 (en) * 2021-04-30 2022-11-03 Progressive Therapeutics Inc Ketamine and cannabis for the treatment of emotional disorders
CN116730853A (zh) * 2022-03-04 2023-09-12 上海致根医药科技有限公司 新型氨基酮类化合物及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384331A (en) * 1991-07-18 1995-01-24 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US20040248964A1 (en) * 2002-11-18 2004-12-09 Crooks Peter A. Analgesic uses of norketamine and ketamine/norketamine prodrugs
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
US7638651B2 (en) * 2007-04-26 2009-12-29 Auspex Pharmaceuticals Substituted cyclohexanones
WO2010120797A2 (en) * 2009-04-13 2010-10-21 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
RU2463049C2 (ru) * 2006-07-19 2012-10-10 Уотсон Лабораториес, Инк. Лекарственные формы с контролируемым высвобождением и соответствующие способы

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CA2922507C (en) 2013-08-26 2022-07-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
EP3215147B1 (en) 2014-11-04 2024-02-28 ACADIA Pharmaceuticals Inc. Neuro-attenuating norketamine compounds and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384331A (en) * 1991-07-18 1995-01-24 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US20040248964A1 (en) * 2002-11-18 2004-12-09 Crooks Peter A. Analgesic uses of norketamine and ketamine/norketamine prodrugs
RU2463049C2 (ru) * 2006-07-19 2012-10-10 Уотсон Лабораториес, Инк. Лекарственные формы с контролируемым высвобождением и соответствующие способы
US7638651B2 (en) * 2007-04-26 2009-12-29 Auspex Pharmaceuticals Substituted cyclohexanones
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
WO2010120797A2 (en) * 2009-04-13 2010-10-21 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAI I et al. Ketamine Metabolism. Identification and Synthesis of Deaminated Products, Journal of Pharmaceutical Sciences, 1985, 74(4), p.486-488. *
LAI I et al. Ketamine Metabolism. Identification and Synthesis of Deaminated Products, Journal of Pharmaceutical Sciences, 1985, 74(4), p.486-488. Sulake, Rohidas S. et al. Synthesis of deuterium labeled ketamine metabolite dehydronorketamine-d4.Bioorganic & Medicinal Chemistry Letters,2011, 21(19), 5719-5721. *
Sulake, Rohidas S. et al. Synthesis of deuterium labeled ketamine metabolite dehydronorketamine-d4.Bioorganic & Medicinal Chemistry Letters,2011, 21(19), 5719-5721. *

Also Published As

Publication number Publication date
DK3215147T3 (da) 2024-04-02
US20220106258A1 (en) 2022-04-07
US10981859B2 (en) 2021-04-20
WO2016073653A1 (en) 2016-05-12
CA2966737A1 (en) 2016-05-12
PT3215147T (pt) 2024-04-18
EP3215147B1 (en) 2024-02-28
US20170355663A1 (en) 2017-12-14
KR20170083575A (ko) 2017-07-18
LT3215147T (lt) 2024-04-25
PL3215147T3 (pl) 2024-06-24
JP6882180B2 (ja) 2021-06-02
US11613515B2 (en) 2023-03-28
KR102604397B1 (ko) 2023-11-21
ES2977383T3 (es) 2024-08-22
HUE066468T2 (hu) 2024-08-28
US11603348B2 (en) 2023-03-14
US10252982B2 (en) 2019-04-09
JP2021120389A (ja) 2021-08-19
SI3215147T1 (sl) 2024-05-31
EP3215147A4 (en) 2018-05-30
EP4393487A3 (en) 2024-08-21
RU2017119222A3 (cg-RX-API-DMAC7.html) 2019-06-07
EP4393487A2 (en) 2024-07-03
CN107106529A (zh) 2017-08-29
AU2015343083A1 (en) 2017-06-08
RU2017119222A (ru) 2018-12-06
FI3215147T3 (fi) 2024-04-18
EP3215147A1 (en) 2017-09-13
US20190263749A1 (en) 2019-08-29
US12466783B2 (en) 2025-11-11
CN115521217A (zh) 2022-12-27
RS65411B1 (sr) 2024-05-31
JP2018501299A (ja) 2018-01-18
AU2015343083B2 (en) 2020-07-23
US20230192593A1 (en) 2023-06-22
US20220402863A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
RU2771275C2 (ru) Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения
US12404257B2 (en) Advantageous benzofuran compositions for mental disorders or enhancement
US12459912B2 (en) Advantageous benzothiophene compositions for mental disorders or enhancement
JP2020189871A (ja) 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
US20180289637A1 (en) Substituted cyclohexanones
JP2003524613A (ja) （−）−ベンラファキシン誘導体並びにその製造方法および使用方法
JP5666140B2 (ja) （−）−ｏ−デスメチルベンラファキシンを含む固形物およびそれらの使用
CZ20013607A3 (cs) Farmaceutický prostředek
US11078153B2 (en) 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase
US12043605B2 (en) Deuterated empathogens
US20250019357A1 (en) Benzofuran salt morphic forms and mixtures for the treatment of mental disorders or mental enhancement
US20250339403A1 (en) Tryptamine Formulations and Uses Thereof
TW202015684A (zh) 那曲酮、納美芬及其衍生物之前藥
US20230321010A1 (en) Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms
US9763904B2 (en) Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds